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Introduction
On January 30th 2020, the WHO declared the international 
outbreak of the new coronavirus SARS-CoV-2 as a public 
health emergency of international concern, as provided 
for in the international health regulation of 2005 [1].
The Severe Acute Respiratory Syndrome (SARS) is known 
to be a “High Consequence Infectious Disease (HCID)” 
also called Infectious Disease of High Consequence 
(IDHC), i.e. a disease which poses a significant threat to 
human health. Patients affected by such diseases usually 
develop severe symptoms and require a high level of 
assistance with death rates that may be quite high [2].
The Apulia Region, starting from January 31st, under a 
decree from the Ministry of Health, established a regional 
Task Force for the management of the infectious outbreak; 
the Task Force arranged the “Operational protocol for the 
management of suspected COVID-19 cases in Apulia” 
and, after the cases reported in Lombardy and Veneto, 
the “COVID-19 Operational plan, Apulia Region”. By 
the Order of the Regional Government No 172, dated 
6 March 2020, within the meaning of Article 11 of D. Lgs. 
No 1/2018 and to transpose the Measures provided for 
in the Document Civil protection operational measures 
for the management of the epidemiological outbreak 
of COVID-19 as referred to in the note of the Head of 
Civil Protection Department – Coordinator of OCDPC 
Interventions No. 630/2020 prot. n. COVID/001656 of 
3 March 2020, the regional Crisis Unit is established to 
take actions and measures, as specifically identified in 
the above-mentioned Document [3].
The scenario of the clinical condition of patients at national 
level is influenced by the fact that it has not yet been 
classified in all Regions and Autonomous Provinces in a 
standardised manner in accordance with the provisions of 
COVID-19 Surveillance, since the structured processing 
of such data is still under preparation. The assessment 
provided by the Italian Institute of Health updated to April 
2nd reported that the clinical condition was available only 
for 39,884 cases, of which 2,360 (5.9%) asymptomatic, 
5,587 (14.0%) paucisymptomatic, 5,155 (12.9%) with 
symptoms whose severity level was not specified, 17,085 
(42.9%) with mild symptoms, 8,494 (21.3%) with severe 
symptoms requiring hospitalisation, 1,203 (3%) with 
clinical picture of critical illness requiring hospitalisation 
in Intensive Care Units [4]. 
From Apulia epidemiological bulletin, updated to 7 April 
2020 [5], it was found that out of 2,514 confirmed 
cases, 938 were in isolation (known in 1,646 cases), 
708  hospitalized (known in 1,646 cases), 209 deceased 
(known in 1,779 cases) and 168 recovered (known in 
1,779 cases). According to the recent literature, the 
clinical process evolution of hospitalized patients has 
shown that 10-20% of patients are hospitalized in a RICU 
(Respiratory Intensive Care Unit), 3-10% are intubated, 
2-5% died [6]. 
The number of hospitalized patients in Apulia (which 
“in large percentage” are the potential patients to 
be discharged) is the reason because of we have 
developed a dedicated project-pathway. It is an original 
organizational model for improving patient safety and 
quality care inside and outside the hospital.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 
is the microorganism responsible for the aggressive Coronavirus 
Disease (COVID-19) pandemic. During the such pandemic, dis-
charge and community reintegration of patients are critical phases 
in guaranteeing public health. A review of the international and 
Italian experiences that represent the best available evidence was 
carried out, mainly focusing on the precise allocation of tasks and 
related responsibilities. The report provides a proposal for a sys-
tematic management pathway dedicated to COVID-19 patients. 
The original result is a logigramme to guide health practitioners 
on discharge and community reintegration of COVID-19 patients. 
To standardize clinical attitudes helps in ensuring quality of care 
and patient safety, should be a core element even during a pub-
lic health emergency. The logigramme suggests, after discharge, 
14 days of further isolation with regular health monitoring and, 
finally, the execution of a nasopharyngeal swab for identification 
of SARS-CoV-2 viral RNA. Home-cared patients should be placed 
on 7 days of further isolation after at least 2 negative RT-PCR 
tests for respiratory tract samples (nasopharyngeal swab). The 
logigramme is already used in the Department of Prevention - 
Local Health Agency of Lecce (Apulia) but it will be updated 
according to the latest research findings. 
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Actually, as recommended by ECDC (European Center 
for Disease Prevention and Control), we answered to 
a strategic clinical governance requirement: define 
the “state of discharge” of patients according to the 
“checklist for the designated treatment facility for HCID 
case (s)” [2].
Purpose and objectives
The mission of the National  –  and therefore 
Regional  –  Healthcare System is to guarantee a “fair 
and appropriate” quality of healthcare. The review of the 
discharge letters of COVID-19 patients from hospital 
units showed the presence of a widely diversified 
de-hospitalization attitude: in case of discharge as a 
consequence of two negative swabs as recommended by 
Italian Ministry of Health [7] or with one negative swab and 
one unknown, it is recommended a 14-days long fiduciary 
isolation, whose follow-up is entrusted to general medicine 
doctors; instead, in other cases, it is simply recommended 
observing common precautionary measures. 
It is necessary to standardize the COVID-19 patients 
discharge from the hospital, in order to have both a 
systemic (shared at a regional level) and a systematic 
perspective and to ensure the healthcare safety.
The final objective of this work is to assess, promote 
and spread guidelines dedicated to the management of 
COVID-19 patients, home-cared or hospitalized ones 
(from hospital discharge to community reintegration).
These guidelines have been developed and calibrated 
based on currently available national and international 
experiences and best evidences. We have developed 
a procedure to be used as a decision support for all 
Healthcare Professionals involved in the COVID-19 care 
system (home cared patients and hospitalized ones). 
This procedure could be reviewed in accordance with 
progressive scientific updates.
Focus on RT-PCR test performed  
using swabs
The most commonly used and reliable test for diagnosis 
of COVID-19 has been the RT-PCR test performed using 
nasopharyngeal swabs or other upper respiratory tract 
specimens, including throat swab or, more recently, saliva.
In most individuals with symptomatic COVID-19 
infection, viral RNA in the nasopharyngeal swab as 
measured by the cycle threshold (Ct) becomes detectable 
as early as day 1 of symptoms and peaks within the first 
week of symptoms onset. Positivity starts to decline by 
week 3 and subsequently becomes undetectable.
The virus persists longer with higher load and peaks later 
in the respiratory tissue of patients with severe disease 
and the duration of the virus was significantly longer in 
men than in women, and significantly longer in patients 
older than 60 years than younger ones [8].
In some cases, viral RNA has been detected by RT-PCR 
even beyond week 6 after the first positive test. A few 
cases have also been reported positive after 2 consecutive 
negative PCR tests performed 24 hours apart [9]. 
The evidence of the extrapulmonary detection of 
viral RNA in both symptomatic and asymptomatic 
subjects is an interesting element from a clinical and 
epidemiological point of view. 
Zou et al. 2020 report that the viral load of asymptomatic 
patients was similar to symptomatic ones, indicating 
a transmission potential of asymptomatic or pre-
symptomatic patients. The study reports that patients 
with few or no symptoms had modest levels of detectable 
viral RNA in the oropharynx for at least 5 days [10].
However, we know that a positive PCR outcome reflects 
only the detection of viral RNA and does not necessarily 
indicate presence of viable virus [11].
Further studies, such as culture of SARS-CoV-2, 
should be carried out to investigate the actual potential 
infectiousness.
It has been reported that several cases recovered from 
COVID-19 tested positive for SARS-CoV-2 after 
discharge (re-detectable positive, RP) but the clinical 
characteristics, significance and potential cause of RP 
patients remained unknown [12].
Four patients with COVID-19 who met criteria for 
hospital discharge or discontinuation of quarantine in 
China (absence of clinical symptoms and radiological 
abnormalities and 2 negative RT-PCR test results) had 
positive RT-PCR test results 5 to 13 days later [13].
In literature there is also a study regarding the case of 
an asymptomatic discharged patient with SARS-CoV-2 
nucleic acid retested positive. Although no scientific 
evidence demonstrated that a discharged patient who 
had repeated SARS-CoV-2 nucleic acid positive could 
be infectious to others, these clinical experiences after 
discharge arouse concern regarding the present discharge 
standard of COVID-19 [14].
All these evidences justify the need for particular attention 
in management during the community reintegration of 
COVID-19 patients to protect public health. 
International review of COVID-19 patients 
discharge 
In order to discharge clinically recovered patients, the 
WHO, CDC and ECDC recommend the collecting of 
two respiratory swabs at least 24 hours apart from each 
other [15-17].
The ECDC reports that, current criteria for discharge 
COVID-19 patient include both resolution of symptoms 
and laboratory evidence of SARS-CoV-2 clearance 
from the upper respiratory tract. Criteria should be 
reviewed according to the local context [18]. The current 
international criteria for discharge are summarised in the 
table written by ECDC [17].
According to some scientifically tested references, under 
unspecified conditions (“if suitable”) home care could 
be performed in symptomatic patients who no longer 
require hospitalization [19].
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On March 24th the CDC clarified that, when clinically 
indicated, COVID-19 patient can be discharged from 
a health care facility. For such patients, a discharge 
does not require that they meet CDC criteria for the 
discontinuation of COVID-19 transmission-based 
precautions (TBP) [20].
CDC guidelines provide a possible dual “destination” for 
discharged COVID-19 patients. For the patient discharged 
home the discharging facility should consider the home’s 
suitability for assuring patient’s isolation and patient’s 
ability to adhere to home isolation recommendations. 
Isolation should be maintained at home if the patient 
returns home before discontinuation of TBP.
For the patients discharged to Long-term Care (LTC) 
or Assisted Living Facilities there are three possible 
scenarios: 
1. when TBPs are still required transferred COVID-19 
patients should go to a facility with adequate personal 
protective equipment and an ability to adhere to 
infection prevention and control recommendations for 
the care of COVID-19 patients. Preferably, the patient 
would be placed at a facility that has already cared for 
COVID-19 cases, in a specific unit designated to care 
for COVID-19 residents; 
2. transferred COVID-19 patients for whom TBPs have 
been discontinued but continue to have persistent 
symptoms of COVID-19 (e.g., a persistent cough) 
should be placed in a single room and be restricted to 
their room; 
3. transferred COVID-19 patients for whom TBPs have 
been discontinued and the symptoms have resolved do 
not require further restrictions. 
ECDC technical report suggests criteria to be considered 
when deciding whether a confirmed COVID-19 case can 
be safely discharged from hospital or released from home 
isolation: the most important factors are the existing 
capacity of the healthcare system, laboratory diagnostic 
resources, and the ongoing epidemiological situation.
“COVID-19 patients may be discharged from hospital 
and moved to home care (or other types of non-hospital 
care and isolation structures) based on: 
• clinical criteria: e.g. no fever for > 3 days, improved 
respiratory symptoms, pulmonary imaging showing 
obvious absorption of inflammation, no hospital care 
needed for other pathology, clinician assessment;
• laboratory evidence of SARS-CoV-2 clearance in 
respiratory samples; 
• 2 to 4 negative RT-PCR tests for respiratory tract 
samples: nasopharynx and throat swabs with sampling 
interval ≥ 24 hours. Testing at a minimum of 7 days 
after the first positive RT-PCR test is recommended 
for patients that clinically improve earlier; 
• serology: appearance of specific IgG when an 
appropriate serological test is available”.
The scientific report suggests, after discharge, 14 further 
days of isolation with regular health monitoring (e.g. 
follow-up visits, phone calls) if, and only if, the patient’s 
home is equipped for patient isolation and the patient 
takes all necessary precautions that we call “self-control” 
(e.g. single room with good ventilation, face-mask, 
reduced close contact with family members, separate 
meals, good hand sanitation, no outdoor activities) in 
order to prevent further spread of SARS-CoV-2 and to 
guarantee public health [17].
The Ministry of Health and Family Welfare, Government 
of the People’s Republic of Bangladesh proposed a 
“Revised Discharge Policy for COVID-19” and the 
classification of the patients based on clinical severity: 
mild/very mild/pre-symptomatic cases; moderate cases 
admitted to dedicated COVID Health Centre (Oxygen 
beds); severe cases including immunocompromised 
(HIV patients, transplant recipients, malignancy). Only 
for the last two categories RT-PCR test is required before 
discharge [21].
National and regional contextualization: 
Lecce’s clinical pathway for hospital 
discharge and community reintegration
By now, in the existing procedures for the management 
of hospital discharge in Italy (in particular in Veneto [22] 
and Liguria [23]) the presence or absence of symptoms 
or clinical recovery is considered a critical element in 
the decision-making procedure. 
Tuscany [24] has developed some guidelines to manage 
the path of the COVID-19 patients inside and outside 
the hospital. These guidelines are considered valid 
and shareable since the positivity/negativity of the 
nasopharyngeal swab is considered fundamental.
Unless there are conditions of absolute unavailability 
to adopt laboratory support, it is considered essential to 
use a “test-based strategy” focused on the execution of 
the pre-discharge Nose-Pharyngeal swab. SARS-CoV-2 
RNA is isolated in only 32% of Oropharyngeal Swabs 
(OP), which is significantly lower if compared to 63% 
of Nasopharyngeal Swabs (NP) [25].
The positive RNA amount reaches the target peak 7-10 
days after the onset of symptoms in the upper respiratory 
tract specimens and subsequently it decreases constantly, 
while in the lower respiratory tract specimen it remains 
higher for 3 weeks after the onset of the disease [26]. 
WHO  [27] and CTS (Italian scientific and technical 
committee)  [28] recommend using NP as standard 
diagnostic approach.
Based on the research of international and national 
sources, the following step-by-step pathway dedicated 
to the COVID-19 patient during hospital de-escalation 
and discharge is proposed.
For hospital de-escalation of patients who no longer 
need (clinical criterion) assistance in Intensive Care, it 
is expected that:
1. if positivity to SARS-CoV-2 persists (ascertained with 
a positive result for the presence of SARS-CoV-2 in 
NP swabs) but clinical stabilization exists (ordinary 
definition criteria), it is expected transferring to a 
COVID-19 normal block hospitalization; 
2. if negative for SARS-CoV-2 (ascertained with a 
negative result for the presence of SARS-CoV-2 in 
2 NP swabs collected at least 24 hours apart) but in 
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need of medical assistance, it is required transferring 
to a NO COVID-19 ordinary hospitalization block; 
3. if prolonged respiratory assistance is needed, it is 
required: respiratory rehabilitation in a structure with 
a dedicated COVID-19 area in case of persistence 
of SARS-CoV-2 positivity (ascertained with a 
positive result for the presence of SARS-CoV-2 in 
NP-swabs); or respiratory rehabilitation in a NON 
COVID-19 structure in case of persistence of SARS-
CoV-2 negativity (ascertained with a negative result 
due to the presence of SARS-CoV-2 in 2 NP-swabs 
collected at least 24 hours apart).
The development of a set of clinical indicators of “clinical 
stabilization” is based on the statistical evaluation of 
the frequency of evidence of the signs related to the 
symptoms presented by COVID-19 patients: 
1. anosmia and ageusia seem to be part of important 
symptoms and clues for the diagnosis of COVID-19, 
mostly in the early stage of the disease [29, 30]; 
2. fever often present with non-constant frequency in 
different cohorts of patients. Despite this COVID-19 
cannot be excluded, even if fever is not present; 
3. gastrointestinal symptoms, about 10% of patients 
develop gastrointestinal symptoms (nausea and/
or diarrhoea), before the insurgence of fever and 
dyspnoea [31];
4. silent hypoxia. In particular elderly can develop 
hypoxia even in absence of dyspnoea symptoms [32].
Recent studies report that COVID-19 could present a 
broader clinical spectrum characterized by the absence 
of any symptoms to heart, digestive tract or Ear-Nose-
Throat (including anosmia and ageusia) manifestations 
and by the presence of peculiar skin manifestations [33].
Physical examination is usually non-specific [6].
Discharge criteria (clinical  +  test-based) proposed by 
Toscana Region [24] that are considered as sharable are 
the following: 
1. at least 48 hours of apyrexia; 
2. saturation level ≥ 94% (≥ 90% for chronic patients) 
in ambient air from at least 48 hours or P/F (PaO2/
FiO2) in ambient air > 300 from at least 48 hours RR 
(Respiratory Rate) < 22 at rest; 
3. two negative nasopharyngeal swabs collected 
24  hours apart and negative test for SARS-CoV-2 
before hospital discharge.
Such criteria have to be fulfilled in order to proceed with 
the next steps of the clinical path dedicated to the patient 
who required hospitalization for COVID-19 treatment.
The logigramme: a community 
reintegration protocol for COVID-19 
patients
We reported the protocol we have developed and already 
applied (Figs. 1, 2):
• If the patient’s discharge to his own home is possible:
1. hospital doctor suggests home isolation for 14 
days;
2. hospital doctor sends the discharge letter to 
DPHCM (Department of Public Health and 
Community Medicine). The letter specifies that 
home isolation is suggested and also clarify that 
the follow-up will be managed by the GP (General 
Practitioner);
3. the DPHCM requires that COVID-19 patients 
have to self-isolate at home, following the already 
existing operating modes prior to evaluation with 
NP swab in case of symptomatic patients, at the 
end of the isolation period.
 During the follow-up the communication between 
GP e DPHCM is constantly guaranteed.
• In case of patient discharge at long-term care facility: 
1. the hospital doctor suggests home isolation for 
further 14 days under the control of the long-term 
care facility. As specified in a local document 
Apulia’s document [34] it’s necessary to provide 
that the facility satisfies technical-logistic-
structural requirements;
2. hospital doctor sends the discharge letter at 
DPHCM; the letter explicit that home isolation is 
required and that the DPHCM is responsible for 
the follow-up phase (also specifies the fields of 
competence and clinical management dependent 
on the GP);
3. the DPHCM requires that COVID-19 patients 
have to self-isolate at home, following the already 
existing operating modes prior to evaluation with 
NP swab in case of symptomatic patients, at the 
end of the isolation period.
 During the follow-up the communication between 
GP, long-term care facility and DPHCM is constantly 
guaranteed.
• Lastly, for the patient that did not need hospitalization 
and that has been managed at his own home, 
community reintegration follows the process as 
below:
1. DPHCM makes the decision of the home isolation 
up to clinical resolution, following the already 
existing operating modes;
2. DPHCM is responsible for the follow-up during 
the home isolation period, as indicated by 
ministry guidelines;
3. the patients, during the follow-up communicate to 
the GP and DPHCM the insurgence of symptoms 
for the fulfilments of respective competences;
4. DPHCM orders the execution of NP swab 
following the pre-set criteria (14 days after the 
first day of isolation and 7 days after the first day 
in absence of symptoms);
5. DPHCM activates 7 further days of home 
isolation after at least 2 negative RT-PCR tests for 
respiratory tract sample (NP swab); 
6. DPHCM requires that COVID-19 patients have 
to self-isolate at home, following the already 
existing operating modes, after 7 days from the 
result of two consecutive negative SARS-CoV-2 
NP swabs (collected 24 hours apart).
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Fig. 1. Logigramme to safe community reintegration for home cared COVID-19 patient.
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 The present pathway could be implemented by integrating 
the serological tests that are now available: they are 
fundamental in finding the virus and for conducting the 
epidemiologic evaluation of viral diffusion, but as OMS 
recommends [35] further evidence is needed about their 
performances and operational utility before their use for 
the SARS-CoV-2 diagnosis [36].
Conclusions
Since COVID-19 is a novel disease, guidance by scientific 
and globally shared evidence is often unavailable: it is 
necessary to urge and promote standardized behavior.
We potentially provide a practical and feasible solution to 
satisfy the need for an optimal community reintegration 
for COVID-19 patients.
The leading idea is sharing a tool of COVID-19 patients 
management, overcoming certain limitations that have 
conditioned the present care system.
The logigramme based on a systematic review is already 
used in our local area: step by step it explains what we 
do and how we do it.
The punctual and rigorous description of tasks and 
related responsibilities should have significant impact 
on single patient’s outcome and public health too.
The real effects of logigramme implementation will be 
studied and analyzed in the second phase of our study 
Fig. 2. Logigramme to safe discharge and community reintegration for hospitalized COVID-19 patient.
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according to the outcome of ongoing studies about viral 
clearance.
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